RxDoctor Payments Data

Supriyo Ghosh, MD

Geriatric Medicine · Camp Hill, PANPI 1366430019

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $469 of the $653 with a category attached, or 71.8%. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 28.2% of the total. Reporting peaked in 2019 at $160 and has fallen 61.8% since, to $61 in 2025.

$653in general payments, 2019–2025

Across 31 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$184
  • Novo Nordisk$120
  • Takeda Pharmaceuticals U.S.A., Inc.$74
  • Lilly USA, LLC$52
  • Novartis$51
  • GSK$32
  • plus $140 from 6 others

What the payments were for

  • Food & beverage$46972%
  • Education$18428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$415,882
Medicare patients
773
Services billed
8,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$183,316
JardianceEmpagliflozin98$119,647
OzempicSemaglutide83$119,446
JanuviaSitagliptin Phosphate75$75,898
MounjaroTirzepatide48$48,446
XareltoRivaroxaban29$38,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$34,853
MyrbetriqMirabegron28$20,355
TrulicityDulaglutide12$18,009
TradjentaLinagliptin15$15,631
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$13,300
ArexvyRsvpref3 Antigen/As01e/Pf41$12,697
Rosuvastatin Calcium397$10,247
Repatha SureclickEvolocumab11$10,144
Atorvastatin Calcium528$8,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$32$187,604196 claims
Novo NordiskOzempic$120$119,44683 claims
MerckJanuvia$26$75,89875 claims
Lilly USA, LLCMounjaro, Trulicity$52$66,45460 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix$32$64,179113 claims
Astellas Pharma US IncMyrbetriq$184$20,35528 claims
AbbVieSynthroid$21$3,357122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →